Skip header and navigation

3 records – page 1 of 1.

Inhibition of experimental choroidal neovascularization by irsogladine, an anti-gastric ulcer agent.
Ophthalmic Res. 2003 May-Jun;35(3):137-42
Publication Type
Akiko Mera Kuroki
Takashi Kitaoka
Yoko Matsuo
Tsugio Amemiya
Author Affiliation
Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Ophthalmic Res. 2003 May-Jun;35(3):137-42
Publication Type
Anti-Ulcer Agents - therapeutic use
Capillaries - drug effects - ultrastructure
Choroid - drug effects - ultrastructure
Choroidal Neovascularization - drug therapy
Comparative Study
Disease Models, Animal
Dose-Response Relationship, Drug
Drug Administration Schedule - veterinary
Drug Evaluation, Preclinical
Laser Coagulation - methods
Microscopy, Electron, Scanning - instrumentation - methods
Rats, Inbred BN
Time Factors
Triazines - therapeutic use
PURPOSE: To determine whether irsogladine inhibits experimental choroidal neovascularization (CNV) induced by laser photocoagulation in pigmented rats. METHODS: Focal laser photocoagulation (argon green 50 mW, 0.04 s, 200 microm) was applied to the retinochoroid of normal Brown Norway rats. Oral administration of irsogladine (5 mg/kg/day or 50 mg/kg/day) was started 1 week before and continued for 2 weeks after laser photocoagulation. Choroidal vascular casts were made 2 weeks after laser photocoagulation and were examined with a scanning electron microscope (SEM). CNV formation was classified according to three grades and evaluated. RESULTS: Laser-induced CNV formation was significantly reduced in rats given 5 mg/kg/day (p
PubMed ID
12711840 View in PubMed
Less detail